EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE     

Skip to content
Myeloma Patients EuropeMyeloma Patients Europe
Search:
  • About us
  • Contact us
Superior MPE
Myeloma Patients Europe
Myeloma Patients EuropeMyeloma Patients Europe
  • Myeloma and AL Amyloidosis
    • Multiple Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • COVID-19
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access
      • Access to myeloma treatment
      • CEE workgroup on Access
      • Myeloma Trial Navigator
  • Educational resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Conference reports
    • Patient guides
  • European Myeloma Day
  • News

Privacy Policy

Cookies Policy

Facebook page opens in new windowTwitter page opens in new windowYouTube page opens in new windowLinkedin page opens in new window

EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Commitee
    • Our funding
    • Get involved in MPE activities
    • Become a MPE member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
      • What is myeloma?
      • What causes myeloma?
      • Coping with a myeloma diagnosis
      • Early diagnosis and smoldering myeloma
      • Diagnostic tests
      • Treatment of myeloma
      • Myeloma symptoms and treatment side-effects
      • Caring for yourself
      • Dealing with the psycho-social aspects of the disease
      • Managing myeloma and work, finance and advance decisions
      • Myeloma landscape and future directions
      • Clinical trials
      • Finding out about myeloma clinical trials
    • About AL amyloidosis
      • Symptoms of AL amyloidosis
      • AL amyloidosis diagnosis
      • Diagnosis challenges
      • AL amyloidosis treatment
      • Living with AL amyloidosis
      • AL amyloidosis: caring for yourself
      • AL amyloidosis treatment side effects
      • Socio-economical impact
      • Advance decisions
      • Novel treatment options in AL amyloidosis
      • AL amyloidosis clinical trials
  • What we do
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • COVID-19
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
    • Research
      • Patient Evidence
      • Horizon Europe
        • MMPredict
        • CARAMBA
      • IMI
        • Harmony
        • Sisaqol
    • Access
      • Access to myeloma treatment
      • CEE workgroup on Access
      • Myeloma and AL Amyloidosis Trial Navigator
  • Educational resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Conference reports
    • Patient guides
  • News
  • European Myeloma Day
    • European Myeloma Day | Learn
    • European Myeloma Day | Share
    • European Myeloma Day | Change
    • Myeloma infographics
    • AL amyloidosis infographics
    • Videos

Daily Archives: January 30, 2023

You are here:
  1. Home
  2. 2023
  3. January
  4. 30

Volunteers of AMEN protesting outside the “Health Basket” Committee conference to include Daratumumab for NDMM patients (December 2021)

Daratumumab approved for first line treatment in Israel

MPE, MyelomaBy Ana VallejoJanuary 30, 2023Leave a comment

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050 Brussels

Belgium

 

© Myeloma Patients Europe 2023

  • Contact
  • About us
  • Privacy Policy
  • Terms and conditions
  • Cookies Policy

  • facebook
    •  
  • twitter
    •  
  • youtube
    •  
  • linkedin
Go to Top